Floatz logo

LIDOCAINE

Lidocaine Adverse Reaction

Pontificia Universidad Catolica de ChileSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Lidocaine Adverse Reaction cohort.

Asset / SponsorPhaseRating
Qinggongshoutao Bolus
Dongzhimen Hospital, Beijing
Phase 4BB
Ginkgo Biloba Extract
Dongzhimen Hospital, Beijing
Phase 4BB
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4
Chang Gung Memorial Hospital
Phase 2B
Thalidomide
Chang Gung Memorial Hospital
Phase 2B
Solu-Cortef
University Medical Center Groningen
Phase 2CCC

View all 17 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →